Evidence map›Paper›PMID 35299743›Full record

ArticleFrontiers in oncology2022

Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer.

Weitao Zhang, Lu Kong, Hongbin Zhu, Decong Sun, Quanli Han, Bin Yan, Zhi Cui, Weiwei Zhang, Shurong Zhang, Xindan Kang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Short-chain fatty acids in cancer pathogenesis.Cancer metastasis reviews · 2023
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Weitao ZhangDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Lu KongDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Hongbin ZhuDepartment of Gastroenterology and Hepatology, Chinese People's Liberation Army (PLA) NO.983 Hospital, Tianjin, China.
Decong SunDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Quanli HanDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Bin YanDepartment of Gastroenterology and Hepatology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Zhi CuiDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Weiwei ZhangDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Shurong ZhangCancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xindan KangDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Guanghai DaiDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Niansong QianDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Wenji YanDepartment of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Chinese People's Liberation Army · CNChinese PLA General Hospital · CNBeijing Tongren Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Aberrant activation of Wnt/β-catenin signaling contributes to the maintenance of cancer stem cells and chemoresistance in colorectal cancer (CRC). Retinoic acid-induced 2 (RAI2) was proved to be a tumor suppressor in CRC in our previous report. In this study, the role of RAI2 in Wnt/β-catenin signaling was further investigated. Methods: As a transcriptional co-regulator, C-terminal Binding Protein 2 (CtBP2) was reported to be involved in Wnt signaling in multiple and complex ways. The correlation of RAI2 and CtBP2 in CRC was analyzed by TCGA dataset, and the interaction between RAI2 and CtBP2 was explored by co-immunoprecipitation (Co-IP) in CRC cells. The effect of RAI2 on the activity of Wnt signaling and the location of β-catenin was detected by Dual-Luciferase reporter assay and Immunofluorescence respectively. Western blotting analysis was performed to detect the expression of target genes involved in Wnt signaling. Sphere formation assay was employed to detect the effect of RAI2 on stem cell like properties. Cell viability assay was used to detect the chemosensitivity of cells before and after transfection of RAI2. Results: The interaction between RAI2 and CtBP2 was confirmed by Co-IP in CRC cells. Besides, the negative correlation of RAI2 and CtBP2 in CRC was found by analyzing the TCGA dataset. Re-expression of RAI2 in human colon cancer cells (HCT116 and LoVo) suppressed the fluorescent activity of Wnt signaling, increased the phosphorylation and inhibited nuclear translocation of β-catenin, with down-regulation of target genes like c-Myc, CyclinD1, ASCL2, and LGR5. In contrast, the mutated RAI2, which can't interact with CtBP2, has no above effects. We observed low expression of RAI2 in 33.89% (101/298) of CRC patients, which was significantly associated with reduced phosphorylation of β-catenin (r=0.8866, P<0.0001), poor 5-year relapse-free survival (RFS) (P = 0.0029) and overall survival (OS) (P = 0.0102). Restoration of RAI2 in HCT116 and LoVo cells inhibited stem cell-like properties of CRC cells and increased chemosensitivity of these cells to oxaliplatin and fluorouracil. Conclusion: Low expression of RAI2 can serve as an independent poor prognostic marker. RAI2 inhibits Wnt signaling by interacting with or down-regulating CtBP2, resulting in repression of stem cell-like properties and increased chemosensitivity of CRC cells.

Indexed as

chemosensitivitycolorectal cancerRAI2stem cell-like propertiesWnt/β-catenin signaling

Identifiers

PMID35299743
PMCPMC8922473
OpenAlexW4214610066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.